Research recommendation(s) from an individual piece of guidance
- Guidance:
- Psoriasis: assessment and management
- Date issued:
-
Research recommendations coming out of this guidance
-
Assessment of disease severity and impact:- In children, young people and adults with psoriasis, can tools be developed and/or existing ones further refined and validated to:
- assess disease severity and impact in both non-specialist and specialist healthcare settings, to facilitate assessment, appropriate referral, treatment planning and measurement of outcomes
- measure burden and cumulative effect of disease activity, severity and impact for people with both psoriasis and psoriatic arthritis?
-
Methotrexate and risk of hepatotoxicity:- What is the impact of methotrexate compared with other approaches to care (for example other systemic non-biological or biological treatments) on risk of significant liver disease in people with psoriasis and do risk factors such as obesity, alcohol use or diabetes alter this risk?
-
Rapid escalation to systemic treatments:- In people with psoriasis, does early intervention with systemic treatments improve the long-term prognosis of psoriasis severity, comorbidities (including psoriatic arthritis), or treatment -related adverse effects, and are there any clinical (for example demographic or phenotypic) or laboratory (for example genetic or immune) biomarkers that can be used to identify those most likely to benefit from this treatment approach?
-
Self-management:- Do structured psoriasis-focused self-management programmes improve patient confidence, wellbeing and disease control compared with standard care?
-
Topical therapy:- In people of all ages with psoriasis: 1. How should topical therapies be used to maintain disease control i) safely; ii) effectively and iii) what are the health economic implications?
2. What are the risks of 'real life' long term corticosteroid use, are there particular people at risk
and what strategies can be used to modify or avoid risks?